Related references
Note: Only part of the references are listed.Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
Kevin C. Conlon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Expansion and Homing of Adoptively Transferred Human Natural Killer Cells in Immunodeficient Mice Varies with Product Preparation and In Vivo Cytokine Administration: Implications for Clinical Therapy
Jeffrey S. Miller et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein
Veronika Bachanova et al.
BLOOD (2014)
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
Neha Korde et al.
HAEMATOLOGICA (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
J. Chu et al.
LEUKEMIA (2014)
Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers
Sawa Ito et al.
MOLECULAR THERAPY (2014)
IL-12 Directs Further Maturation of Ex Vivo Differentiated NK Cells with Improved Therapeutic Potential
Dorit Lehmann et al.
PLOS ONE (2014)
PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection
Alexander W. MacFarlane et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects
Mamata S. Gokhale et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2014)
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
Rizwan Romee et al.
BLOOD (2013)
CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia
Margaret L. Green et al.
BLOOD (2013)
Growth and Activation of Natural Killer Cells Ex Vivo from Children with Neuroblastoma for Adoptive Cell Therapy
Yin Liu et al.
CLINICAL CANCER RESEARCH (2013)
Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition
Andres Wiernik et al.
CLINICAL CANCER RESEARCH (2013)
Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study
Christine Wolschke et al.
EXPERIMENTAL HEMATOLOGY (2013)
Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling
Erik Wennerberg et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Bringing natural killer cells to the clinic: ex vivo manipulation
Richard W. Childs et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Therapeutic applications: natural killer cells in the clinic
Jeffrey S. Miller
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function
Bree Foley et al.
BLOOD (2012)
Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7
Srinivas S. Somanchi et al.
BLOOD (2012)
Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences
Heather E. Eve et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications
Natalia Lapteva et al.
CYTOTHERAPY (2012)
A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies
Noriko Shimasaki et al.
CYTOTHERAPY (2012)
Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD
Silke Wiesmayr et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2012)
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy
Tarun K. Garg et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
Nidale Tarek et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Human Cytomegalovirus (CMV)-Induced Memory-like NKG2C+ NK Cells Are Transplantable and Expand In Vivo in Response to Recipient CMV Antigen
Bree Foley et al.
JOURNAL OF IMMUNOLOGY (2012)
Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production
Michelle K. Gleason et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'
Aron M. Levin et al.
NATURE (2012)
Anti-CD20 Antibody Therapy for B-Cell Lymphomas
David G. Maloney
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Cecele J. Denman et al.
PLOS ONE (2012)
Interleukin-15 biology and its therapeutic implications in cancer
Jason C. Steel et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2012)
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
Antonio Curti et al.
BLOOD (2011)
Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients
Ahmet H. Elmaagacli et al.
BLOOD (2011)
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
Don M. Benson et al.
BLOOD (2011)
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response
Asher A. Chanan-Khan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization
Kai-Ping Han et al.
CYTOKINE (2011)
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
Melissa A. Geller et al.
CYTOTHERAPY (2011)
Interleukin (IL)-2 and IL-15 have different effects on human natural killer lymphocytes
Anne-Helene Pillet et al.
HUMAN IMMUNOLOGY (2011)
Safety, Pharmacokinetics, and Immunomodulatory Effects of Lenalidomide in Children and Adolescents With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome: A Children's Oncology Group Phase I Consortium Report
Stacey L. Berg et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Selenite Induces Posttranscriptional Blockade of HLA-E Expression and Sensitizes Tumor Cells to CD94/NKG2A-Positive NK Cells
Monika Enqvist et al.
JOURNAL OF IMMUNOLOGY (2011)
Activating Signals Dominate Inhibitory Signals in CD137L/IL-15 Activated Natural Killer Cells
Hua Zhang et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Expansion of a unique CD57+ NKG2Chi natural killer cell subset during acute human cytomegalovirus infection
Sandra Lopez-Verges et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
Guellue Goerguen et al.
BLOOD (2010)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method
L. Li et al.
CANCER GENE THERAPY (2010)
Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer
Jan Pander et al.
EUROPEAN JOURNAL OF CANCER (2010)
In vivo tumor cell rejection induced by NK cell inhibitory receptor blockade: Maintained tolerance to normal cells even in the presence of IL-2
Gustaf Vahlne et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
IL-15Rα-IgG1-Fc Enhances IL-2 and IL-15 Anti-tumor Action through NK and CD8+ T Cells Proliferation and Activation
Zhongfu Wu et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2010)
Safety and immunologic effects of IL-15 administration in nonhuman primates
Carolina Berger et al.
BLOOD (2009)
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
Francois Romagne et al.
BLOOD (2009)
Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells
Andreas Lundqvist et al.
BLOOD (2009)
Replicative potential of human natural killer cells
Hiroyuki Fujisaki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells
Maria Berg et al.
CYTOTHERAPY (2009)
Interleukin-12 Receptor β2: From Cytokine Receptor to Gatekeeper Gene in Human B-Cell Malignancies
Vito Pistoia et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cutting Edge: The Metalloproteinase ADAM17/TNF-α-Converting Enzyme Regulates Proteolytic Shedding of the MHC Class I-Related Chain B Protein
Philippe Boutet et al.
JOURNAL OF IMMUNOLOGY (2009)
A Programmed Switch from IL-15-to IL-2-Dependent Activation in Human NK Cells
Anne-Helene Pillet et al.
JOURNAL OF IMMUNOLOGY (2009)
Differential Effects of Selenium on Benign and Malignant Prostate Epithelial Cells: Stimulation of LNCaP Cell Growth by Noncytotoxic, Low Selenite Concentrations
Nur Oezten Kandas et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2009)
Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo
Caroline Sola et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation
Jumei Shi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Immunomodulatory drugs Revlimid (R) (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation
Dan Zhu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors
Mar Vales-Gomez et al.
CANCER RESEARCH (2008)
Line of attack: NK cell specificity and integration of signals
Yenan T. Bryceson et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Preassociation of IL-15 with IL-15Rα-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action
Sigrid Dubois et al.
JOURNAL OF IMMUNOLOGY (2008)
Multilineage hematopoietic recovery with concomitant antitumor effects using low dose Interleukin-12 in myelosuppressed tumor-bearing mice
Lena A. Basile et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2008)
NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities
Stefan Diermayr et al.
BLOOD (2008)
The trafficking of natural killer cells
Claude Gregoire et al.
IMMUNOLOGICAL REVIEWS (2007)
FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma
Dong Hwan Kim et al.
BLOOD (2006)
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2
Delphine Merino et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Human NK cell education by inhibitory receptors for MHC class I
Nicolas Anfossi et al.
IMMUNITY (2006)
Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: A novel method to potentiate natural killer cell tumor cytotoxicity
Andreas Lundqvist et al.
CANCER RESEARCH (2006)
Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells
B Husbeck et al.
PROSTATE (2006)
Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B
S Skov et al.
CANCER RESEARCH (2005)
Licensing of natural killer cells by host major histocompatibility complex class I molecules
S Kim et al.
NATURE (2005)
Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D Ligands by the histone deacetylase inhibitor sodium valproate
S Armeanu et al.
CANCER RESEARCH (2005)
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells
C Imai et al.
BLOOD (2005)
A single administration of recombinant human interleukin-12 is associated with increased expression levels of interferon-gamma and signal transducer and activator of transcription in healthy subjects
C Trudeau et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
JS Miller et al.
BLOOD (2005)
Differential effects of selenite and selenate on human melanocytes, keratinocytes, and melanoma cells
L Bandura et al.
BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE (2005)
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
T Hayashi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow
LJ Xia et al.
BLOOD (2004)
The IL-12 signature: NK cell terminal CD56(+high) stage and effector functions
MJ Loza et al.
JOURNAL OF IMMUNOLOGY (2004)
Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma
JA Gollob et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
L Ruggeri et al.
SCIENCE (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
FE Davies et al.
BLOOD (2001)
Share Paper
